Loading…
Pharming Group N.V. is projected to rise to $11.75 by 2027, a +17% move from its current price of $10.08. PHAR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $9.75 | $10.08 | $10.43 | +0.01% |
| Aug 3 | $9.61 | $10.08 | $10.58 | +0.03% |
| Aug 4 | $9.51 | $10.08 | $10.69 | +0.04% |
| Aug 5 | $9.42 | $10.09 | $10.79 | +0.05% |
| Aug 6 | $9.35 | $10.09 | $10.88 | +0.07% |
| Aug 7 | $9.28 | $10.09 | $10.96 | +0.08% |
| Aug 8 | $9.22 | $10.09 | $11.04 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $9.22 | $10.09 | $11.04 | +0.09% |
| Week 2 | $8.90 | $10.10 | $11.46 | +0.18% |
| Week 3 | $8.65 | $10.11 | $11.81 | +0.27% |
| Week 4 | $8.46 | $10.12 | $12.10 | +0.37% |
| Week 5 | $8.29 | $10.13 | $12.37 | +0.46% |
| Week 6 | $8.14 | $10.14 | $12.62 | +0.55% |
| Week 7 | $8.00 | $10.14 | $12.86 | +0.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
Its lead product RUCONEST is a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K?
inhibitor.
The company has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
PHAR trades at $10.75 and has a market capitalization of $760.86M, with a market rank of 2554. These numbers place the stock in the lower tiers by size but provide a basis for evaluating its price trajectory.
The 30-day price range is $8.70 to $13.28, with a support level at $10.75 and a resistance level at $14.46. This framing helps outline short-term risk and potential upside.
Forecasts indicate a near-term price path that starts at a 2026 average of $10.75 with a max of $15.07 and a neutral stance, followed by a long-run bullish trajectory that climbs to a 2031 average of $18.24 and ultimately to a 2050 average of $74.80. These figures imply meaningful upside over the extended horizon while acknowledging near-term uncertainty.
A major floor 29.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 43.5% above — a clean break opens room to run.
A major ceiling 76.6% above — clearing it would confirm fresh momentum.
Key PHAR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.74 | Sell | $11.37 | Sell |
| MA 10 | $12.37 | Sell | $12.07 | Sell |
| MA 20 | $13.10 | Sell | $12.63 | Sell |
| MA 50 | $13.01 | Sell | $13.27 | Sell |
| MA 100 | $14.40 | Sell | $14.03 | Sell |
| MA 200 | $15.47 | Sell | $14.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 21.90 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -271.56 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.33 | Sell |
| ROC (12) | -24.78 | Sell |
| Bollinger %B (20,2) | -0.20 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.19 | Sell |
| Awesome (5,34) | -1.36 | Sell |
| Ultimate (7,14,28) | 17.67 | Buy |
| Momentum (10) | -3.39 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 10.82 | Sell |
| ADX (14) | 20.24 | Sell |
| ATR (14) | 0.38 | Info |
The market sentiment is NEUTRAL and the momentum indicators are modest at present. The RSI(14) is 30, suggesting oversold conditions that could be used by traders for tactical entries or risk management.
The 50-day simple moving average (SMA50) sits at $13.06, while the 200-day simple moving average (SMA200) is at $15.49. The price currently sits around the $10.75 support level, with resistance pegged at $14.46.
The 30-day price range spans from a low of $8.70 to a high of $13.28, providing a window into recent volatility and potential near-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $10.08 | $10.08 | $14.19 | 0% | Neutral | |
| $9.17 | $11.75 | $16.05 | +17% | Neutral | |
| $9.88 | $13.14 | $18.76 | +30% | Bullish | |
| $9.38 | $12.84 | $19.00 | +27% | Bullish | |
| $9.45 | $13.28 | $20.22 | +32% | Bullish | |
| $11.17 | $16.08 | $25.12 | +60% | Bullish | |
| $12.68 | $18.69 | $29.85 | +85% | Bullish | |
| $14.22 | $21.41 | $34.90 | +112% | Bullish | |
| $15.09 | $23.19 | $38.51 | +130% | Bullish | |
| $15.29 | $23.96 | $40.49 | +138% | Bullish | |
| $21.44 | $36.77 | $66.76 | +265% | Bullish | |
| $31.21 | $62.82 | $126.46 | +523% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $10.08 | $10.08 | $12.58 | +0.00% |
| September 2026 | $8.60 | $10.24 | $12.60 | +1.61% |
| October 2026 | $8.49 | $10.20 | $12.72 | -0.41% |
| November 2026 | $8.88 | $10.74 | $13.53 | +5.32% |
| December 2026 | $9.17 | $11.16 | $14.19 | +3.89% |
Click any year to see its month-by-month PHAR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Pharming Group N.V.'s 2026 outlook centres on $10.08, within a $10.08 to $14.19 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, PHAR could reach as high as $16.05, with a base case around $11.75 and support toward $9.17 — roughly +17% from $10.08. A consolidation phase looks the most probable path here.
Expect PHAR to range from $9.88 to $18.76 through 2028. The $13.14 average target implies a +30% move from current prices. That is up +12% on the projected 2027 average. Momentum favours further upside here.
The PHAR price prediction for 2029 points to an average of $12.84 (low $9.38, high $19.00) — a potential gain of +27% on today's $10.08. Buyers look set to stay in control over this stretch.
In 2030, PHAR is projected to trade between $9.45 and $20.22, averaging $13.28 — a potential gain of +32% from today's $10.08. That is up +3% on the projected 2029 average. Momentum favours further upside here.
Pharming Group N.V.'s 2031 outlook centres on $16.08, within a $11.17 to $25.12 range. That is up +21% on the projected 2030 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, PHAR could reach as high as $29.85, with a base case around $18.69 and support toward $12.68 — roughly +85% from $10.08. Momentum favours further upside here.
Expect PHAR to range from $14.22 to $34.90 through 2033. The $21.41 average target implies a +112% move from current prices. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The PHAR price prediction for 2034 points to an average of $23.19 (low $15.09, high $38.51) — a potential gain of +130% on today's $10.08. Momentum favours further upside here.
In 2035, PHAR is projected to trade between $15.29 and $40.49, averaging $23.96 — a potential gain of +138% from today's $10.08. That is up +3% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Pharming Group N.V.'s 2040 outlook centres on $36.77, within a $21.44 to $66.76 range. That is up +53% on the projected 2035 average. That marks a +265% change versus current levels. Momentum favours further upside here.
By 2050, PHAR could reach as high as $126.46, with a base case around $62.82 and support toward $31.21 — roughly +523% from $10.08. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAR today (≈ 99.206349 PHAR) could be worth
$6,231.91
+$5,231.91 (+523%) by 2050 · US Dollar
Based on the average projected PHAR price of $62.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHARwould be worth at today's price.
$1,000 invested in PHAR on Jul 31, 2025 (≈ 90.009004 PHAR) would be worth
$907.29
-$92.71 (-9.3%) today · 0.91× · US Dollar
Based on a PHAR entry price of $11.11 vs. today's $10.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.61 | $799.05 | -20.1% |
| 1 month ago | $13.66 | $738.14 | -26.2% |
| 3 months ago | $16.98 | $593.64 | -40.6% |
| 6 months ago | $16.98 | $593.81 | -40.6% |
| 1 year ago | $11.11 | $907.29 | -9.3% |
| All time (5.0y) ago | $11.4 | $884.21 | -11.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAR forecast.
Our base-case forecast reaches $20.00 around 2033.
Implied market cap at $20.00: $1.42B
The multi-year forecast shows a sustained uptrend from 2026 onward. The 2026 forecast is an average of $10.75 with a max of $15.07, and a 0% ROI, reflecting a neutral near-term stance.
From 2027 to 2030, the average price progresses to $12.67, $14.31, $14.20, and $14.90 respectively, with ROIs of 17.8%, 33.1%, 32.1%, and 38.6% as the outlook improves.
The forecast continues to be bullish into the early 2030s, with 2031 averaging $18.24 (ROI 69.7%), 2032 $21.27 (ROI 97.8%), 2033 $24.29 (ROI 125.9%), 2034 $26.44 (ROI 145.9%), and 2035 $27.42 (ROI 155.1%).
The path extends to 2040 with an average of $42.98 (ROI 299.8%), and to 2050 with an average of $74.80 (ROI 595.9%), all indicating a bullish trajectory over the long term. These are estimates and not guarantees, reflecting potential upside and the inherent uncertainty in future markets.
Tap a question to reveal the answer.
2030 forecast shows an average of $14.90 with a min of $10.72 and a max of $22.41; ROI 38.6%; sentiment BULLISH.
Long-term forecasts show a bullish trajectory, with 2040 average of $42.98 and 2050 average of $74.80 and ROIs of 299.8% and 595.9%, respectively. Near term (2026) is neutral with an average of $10.75 and ROI of 0%.
Yes. The 2031 forecast shows an average of $18.24 with a max of $28.11, indicating the possibility of surpassing $20 within the forecast window.
Current price is $10.75 and market capitalization is $760.86M. The stock is ranked 2554 by market cap.
The 2040 forecast shows an average of $42.98 with a max of $76.55 and a min of $25.72; ROI 299.8% and sentiment BULLISH.
Pharming Group N.V. Community Discussion
0Share your Pharming Group N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.